Studying the Time of Humankind

Medytox is a biopharmaceutical company studying the time of humankind.

Our Products

We are relentlessly driving our growth to claim the No. 1 spot in global medical aesthetics.

Neuronox

Botulinum Toxin Type A

Driven by R&D

We build a better tomorrow through our dedication to life and time.

01

Medytox focuses its research capabilities on botulinum toxin pharmaceuticals as a core portfolio.

Our cultivation and purification technologies for botulinum toxin are globally recognized as a key competitive strength.

02

Medytox has developed three hyaluronic acid fillers with proprietary technology.

Building on safety and efficacy, we expand clinical value and broaden the portfolio through medical device research covering aesthetic and therapeutic indications.

03

With innovative technology and differentiated R&D capabilities, Medytox has also entered the chemical pharmaceuticals market.

To address patient inconvenience, we developed the world’s first cholic acid–based injectable adipocytolytic agent, recognized by Korea’s MFDS as the 40th domestically developed new drug.

Global Leadership

Medytox, a global biopharmaceutical company,
is gaining recognition in global markets beyond Korea.

Global Network
+
Countries Exported
R&D Investment
%
of Total Revenue
Core Technology
The World’s Only Independent Developer of Three Distinct Botulinum Toxin Products
Innovation
The World's First Cholic Acid Based Injectable Adipocytolytic Agent

Press Release

Stay updated with the latest news from Medytox.

Medytox Holds 2026 Global Anatomy Workshop in Bangkok

Medytox Holds 2026 Global Anatomy Workshop in Bangkok

Medytox signs botulinum toxin distribution agreement worth USD 73 million with Blau Farmacêutica, from Brazil

Medytox signs botulinum toxin distribution agreement worth USD 73 million with Blau Farmacêutica, from Brazil

Medytox’s Sweeping Victory in Botulinum Toxin Suit against Daewoong

Medytox’s Sweeping Victory in Botulinum Toxin Suit against Daewoong

The United States International Trade Commission (ITC) decided to institute an investigation into unlawful acts against Hugel, Inc., Hugel America, Inc., and Croma Pharma GmbH

The United States International Trade Commission (ITC) decided to institute an investigation into unlawful acts against Hugel, Inc., Hugel America, Inc., and Croma Pharma GmbH

Medytox retained a world-class law firm ‘Quinn Emanuel Urquhart & Sullivan, LLP’… to pursue its legitimate rights to the company’s intellectual property

Medytox retained a world-class law firm ‘Quinn Emanuel Urquhart & Sullivan, LLP’… to pursue its legitimate rights to the company’s intellectual property

Medytox signs a settlement agreement with AEON Biopharma… U.S. litigations are concluded

Medytox signs a settlement agreement with AEON Biopharma… U.S. litigations are concluded

Medytox, Allergan, and Evolus announce settlement of intellectual property litigation

Medytox, Allergan, and Evolus announce settlement of intellectual property litigation

The full text of the final determination by the U.S. International Trade Commission is released, ‘Daewoong acquired Medytox’s strain by improper means’

The full text of the final determination by the U.S. International Trade Commission is released, ‘Daewoong acquired Medytox’s strain by improper means’

The US ITC’s Administrative Law Judge found Daewoong Pharmaceutical misappropriated Medytox’s strain…Recommended that the import of 'Nabota' be banned for 10 years

The US ITC’s Administrative Law Judge found Daewoong Pharmaceutical misappropriated Medytox’s strain…Recommended that the import of 'Nabota' be banned for 10 years

The U.S. ITC Commissioners, ‘Decided to review certain portions of the initial determination from some of Daewoong’s objections’…’the review is merely a routine and regular practice’

The U.S. ITC Commissioners, ‘Decided to review certain portions of the initial determination from some of Daewoong’s objections’…’the review is merely a routine and regular practice’

Follow us

#NEURADERM

#LactiPLAN TVC

#CORE TIME

#LactiPLAN